Horizon Therapeutics PLC (HZNP): Price and Financial Metrics


Horizon Therapeutics PLC (HZNP): $79.76

-2.74 (-3.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HZNP POWR Grades


  • HZNP scores best on the Sentiment dimension, with a Sentiment rank ahead of 90.78% of US stocks.
  • HZNP's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • HZNP ranks lowest in Momentum; there it ranks in the 8th percentile.

HZNP Stock Summary

  • HZNP has a market capitalization of $24,051,085,991 -- more than approximately 89.32% of US stocks.
  • HZNP's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 251.19 -- higher than 89.87% of US-listed equities with positive expected earnings growth.
  • With a year-over-year growth in debt of 156.26%, Horizon Therapeutics Public Ltd Co's debt growth rate surpasses 92.91% of about US stocks.
  • Stocks that are quantitatively similar to HZNP, based on their financial statements, market capitalization, and price volatility, are NICE, TRIP, STAA, TWOU, and ETSY.
  • HZNP's SEC filings can be seen here. And to visit Horizon Therapeutics Public Ltd Co's official web site, go to www.horizontherapeutics.com.

HZNP Valuation Summary

  • In comparison to the median Healthcare stock, HZNP's price/sales ratio is 15.42% lower, now standing at 9.6.
  • HZNP's EV/EBIT ratio has moved up 65.2 over the prior 123 months.
  • Over the past 123 months, HZNP's price/sales ratio has gone down 35.9.

Below are key valuation metrics over time for HZNP.

Stock Date P/S P/B P/E EV/EBIT
HZNP 2021-08-31 9.6 6 47.1 60.1
HZNP 2021-08-30 9.6 6 47.4 60.4
HZNP 2021-08-27 9.6 6 47.2 60.2
HZNP 2021-08-26 9.6 6 47.2 60.1
HZNP 2021-08-25 9.6 6 47.5 60.6
HZNP 2021-08-24 9.6 6 47.2 60.2

HZNP Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -3.61%.
  • Its 2 year net cashflow from operations growth rate is now at 54.81%.
  • The 3 year net cashflow from operations growth rate now stands at -2.37%.
HZNP's revenue has moved up $2,134,048,000 over the prior 52 months.

The table below shows HZNP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 3,226.41 1,035.271 534.491
2021-09-30 2,957.26 906.531 551.866
2021-06-30 2,556.695 604.354 518.163
2021-03-31 2,186.926 614.553 280.036
2020-12-31 2,200.429 555.688 389.796
2020-09-30 1,818.66 337.251 792.008

HZNP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HZNP has a Quality Grade of C, ranking ahead of 61.77% of graded US stocks.
  • HZNP's asset turnover comes in at 0.385 -- ranking 123rd of 681 Pharmaceutical Products stocks.
  • VNDA, NEOG, and CEMI are the stocks whose asset turnover ratios are most correlated with HZNP.

The table below shows HZNP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.385 0.758 0.134
2021-06-30 0.367 0.759 0.130
2021-03-31 0.361 0.755 0.125
2020-12-31 0.425 0.758 0.237
2020-09-30 0.382 0.744 0.142
2020-06-30 0.357 0.734 0.038

HZNP Price Target

For more insight on analysts targets of HZNP, see our HZNP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $132.84 Average Broker Recommendation 1.33 (Strong Buy)

HZNP Stock Price Chart Interactive Chart >

Price chart for HZNP

HZNP Price/Volume Stats

Current price $79.76 52-week high $120.54
Prev. close $82.50 52-week low $78.85
Day low $79.42 Volume 2,618,400
Day high $82.34 Avg. volume 1,892,587
50-day MA $90.57 Dividend yield N/A
200-day MA $101.02 Market Cap 18.34B

Horizon Therapeutics PLC (HZNP) Company Bio


Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.


HZNP Latest News Stream


Event/Time News Detail
Loading, please wait...

HZNP Latest Social Stream


Loading social stream, please wait...

View Full HZNP Social Stream

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

DUBLIN, February 23, 2022--Horizon Therapeutics announces the initiation of a Phase 3 trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of active TED.

Yahoo | February 23, 2022

Horizon Therapeutics Brings in Big Money

Horizon Therapeutics Public Limited Company (HZNP) stock has been hot recently, gaining 8.0% over the past month.

FX Empire | February 22, 2022

Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference

DUBLIN, February 21, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will present at the following conference in March:

Yahoo | February 21, 2022

Horizon Therapeutics'' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation

Horizon Therapeutics plc (NASDAQ: HZNP ) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis Optica Spectrum Disorder (NMOSD) . The data will be presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society. NMOSD is a neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain, and … Full story available on Benzinga.com

Benzinga | February 16, 2022

Horizon''s Uplizna reduces severity of attacks in neuro disease

Horizon Therapeutics (HZNP) said a new analysis showed that Uplizna reduced the severity of attacks and levels of key disease-related biomarkers in people with Neuromyelitis…

Seeking Alpha | February 16, 2022

Read More 'HZNP' Stories Here

HZNP Price Returns

1-mo -10.87%
3-mo -25.56%
6-mo -25.98%
1-year -17.42%
3-year 222.13%
5-year 571.95%
YTD -25.98%
2021 47.31%
2020 102.07%
2019 85.26%
2018 33.84%
2017 -9.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6348 seconds.